Chinese CRO Paramax Agrees To Be Acquired By RPS Of U.S.
This article was originally published in PharmAsia News
Executive Summary
China's Paramax International, a contract-research organization, has agreed to be acquired by the U.S. CRO, ReSearch Pharmaceutical Services, for $1 million in cash and 530,973 shares of RPS common stock. RPS said the Chinese company would serve as its base in Asia once the deal is sealed in May. RPS earlier acquired three small European CROs as part of its effort to expand its support system for drug development. Paramax headquarters are in Beijing, with an operations office in Shanghai. (Click here for more
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.